🔬 A Cytology Lesson:
One Marker • Two Histories • Three Primaries !!!
👩⚕️ Patient
• 72-year-old female with pleural effusion
• Initial history provided: Previous h/o anal squamous cell carcinoma and breast carcinoma
🔍 Cytology Findings
• Highly cellular specimen
• Malignant epithelial cells in clusters and 3D groups
• Marked nuclear atypia
• Occasional vacuolated cytoplasm
🧪 Initial Cell Block IHC
✅ BerEP4 positive
❌ Calretinin negative
✅ CK7 positive
❌ CK20 negative
🎯 Diagnostic Approach Based on Available History
• TTF1 → to exclude primary lung adenocarcinoma
• p63 → to assess squamous differentiation
• TRPS1 → to evaluate possible breast origin
📋 Results
❌ TTF1 negative
❌ p63 negative
✅ TRPS1 patchy positive
⚠️ The Pitfall
With a history of breast carcinoma and a CK7 /TRPS1 profile, metastatic breast carcinoma seemed highly likely.
🔄 The Turning Point
• TRPS1 positivity was only patchy
• Additional clinical information was obtained
• Histologic correlation was performed
🧩 The Missing History
The patient also had a recently diagnosed endometrial malignancy with frozen pelvis and extensive local spread, a crucial piece of information that was not initially available.
🧬 Further Workup
✅ PAX8 positive - favor mullerian
❌ GATA3 negative - point against breast cancer
📌 Final Interpretation
Metastatic Müllerian carcinoma, with correlation favoring high-grade serous carcinoma.
💡 Take-Home Messages
✔️ TRPS1 is a useful marker, but not entirely specific for breast carcinoma.
✔️ Patchy TRPS1 positivity can be seen in Müllerian serous carcinomas and other non-mammary tumors.
✔️ Never interpret immunostains in isolation.
✔️ Morphology Clinical History Imaging Histology Correlation = Accurate Diagnosis.
✔️ Always question a result that does not perfectly fit the overall picture.
🏆 Lesson Learned
💎 The most important diagnostic tool in this case was not TRPS1—it was the missing clinical history.
#Cytopathology #PleuralFluid #DiagnosticPitfall #TRPS1 #BreastPathology #PathologyPearls #Cytology #ClinicopathologicCorrelation #PathTwitter #MedEd #LearningFromCases